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Abstract 
We report the successful treatment of plaque-like sclerodermiform mucinosis using 
tacrolimus ointment topically. We present a 70-year-old male with a large chronic 
erythema and hardening of the nuchal skin and shoulder area. Subjective symptoms 
were a moderate pruritus and a rather disabling stiffness. A biopsy specimen revealed 
typical features of lichen myxedematosus. In a subsequent clinical examination, no 
associated illnesses such as hypothyroidism or gammopathy were found. Since no 
established therapy exists for this condition, and as there was a lack of response to 
potent topical glucocorticosteroids, tacrolimus 0.03% ointment was used off-label twice 
daily. Surprisingly, this resulted in a rapid, almost complete clearance of the skin within 
three weeks of treatment. 
 
Case Report 
A 70-year-old male patient presented with a 2-month history of an extensive erythematous plaque, 
dermo-epidermal thickening, and progressive scleroderma-like hardening of the skin on the neck and 
shoulder area. A close-up view showed small, merging, lichenoid papules (fig. 1). 
The medical history was negative for other skin diseases. The subjective symptoms were a moderate 
pruritus and a rather disabling progressive stiffness of the nuchal area as well as of the shoulder area. No 
topical therapy had been applied yet. Co-existing medical conditions included spino-bulbar muscle 
dystrophia (type Kennedy), diabetes mellitus and a resected carcinoma of the urinary bladder. 
A laboratory work-up including complete blood cell count and comprehensive screening for viral 
hepatitis, Borrelia serology as well as erythrocyte sedimentation rate, C-reactive protein, 
hemostaseology and urine analysis were normal. Increased thyroid autoantibodies were present 
(thyroglobulin-antibodies, 469 IU/ml; thyroperoxidase antibodies, 192 IU/ml); however, peripheral  
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thyroid hormones were normal. Paraproteins were detected neither in the serum nor in the urine by 
electrophoresis and immunofixation, respectively. 
A 6-mm punch biopsy from the left upper back was obtained for histopathologic analysis. 
Hematoxylin-eosin staining showed a partial loss of rete ridges in an otherwise normal epidermis. Basal 
keratinocytes were strongly pigmented, and stained positive with Fontana-Masson melanin stain. The 
dermis showed a subtle superficial perivascular inflammatory lymphocytic infiltrate and prominent 
perifollicular and interstitial deposition of mucin without a substantial increase of interstitial fibroblasts. 
The mucin was highlighted with colloidal iron staining (fig. 2). The patient received treatment with 
topical steroids (0.1% mometasone) for 8 weeks which yielded neither a subjective nor an objective 
improvement of the skin lesions. Hence, topical treatment was changed to 0.03% tacrolimus (Protopic) 
twice daily, resulting in a nearly complete reduction of hardening and erythema of the previously 
affected skin within three weeks. Due to the good clinical response to this therapy, no vehicle control 
was performed. 
Discussion 
Cutaneous mucinoses comprise different entities with diffuse or focal deposition of 
mucin. Mucin consists of a mixture of glycosaminoglycans (hyaluronic acid/dermatan 
sulfate) either unbound (e.g. hyaluronic acid) or protein-bound (e.g. proteoglycan). Most 
glycosaminoglycans are generated by fibroblasts and/or keratinocytes. 
In 1969, Montgomery and Underwood [1] first made a distinction between lichen 
myxedematosus (LM), scleromyxedema, and generalized myxedema by means of 
different clinical patterns. 
More recently, according to different etiologies, pathogenesis and skin distribution, a 
classification has been set up by Rongioletti and Rebora differentiating three major 
categories: (a) generalized mucinosis (scleromyxedema), (b) localized and (c) atypical 
forms [2]. The localized variants comprise five subtypes including discrete papular LM, 
acral persistent papular mucinosis, juvenile and adult variant of self-healing papular 
mucinosis, papular mucinosis of the infancy and nodular LM [3, 4, 2, 5]. As the 
morphology of the case reported herein does not fit well into the localized variants as 
described, we would assign our observation to the third group of the atypical forms of 
mucinoses. More typical localized variants present with skin-colored to reddish, firm 
papules or nodules on the upper extremities, trunk, thigh and sometimes on acral skin. 
Clinical differentials of LM include granuloma annulare, all other kinds of lichen (ruber, 
amyloidosus, etc.), reticulate erythematous mucinosis (REM) syndrome and, if diffuse, 
scleredema of Buschke. 
Histopathologically, the hallmarks of localized mucinosis are deposition of mucin with 
a varying degree of proliferating fibroblasts and a whirly arrangement of collagen bundles 
in late stages of the disease. Perivascular lymphocytic infiltrates can be observed. 
The histologic differentials in case of discrete or marginal fibroblast proliferation 
include myxedema and scleredema. Therefore, the diagnosis requires an analysis of the 
clinical picture and associated illnesses. As a rule, localized papular mucinoses are only 
exceptionally associated with hepatitis C, HIV/AIDS, monoclonal gammopathy, or 
plasmocytoma. 
To date, no guidelines for the treatment of localized mucinoses exist. Usually, topical 
steroids are used as first-line therapy. Circumscribed surgery, dermabrasion or laser 
therapy (carbon dioxide laser) can also be considered. In generalized forms, application of  
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systemic steroids, chlorambucil, cyclophosphamide, aromatic retinoids, or chloroquine 
has been reported [6]. 
Topical tacrolimus or pimecrolimus have been reported as useful in rather discrete 
variants [6, 7, 8]. Transforming growth factor-beta and tumor necrosis factor-alpha are 
thought to play a major role in the pathogenesis of localized mucinosis [7]. Thus, positive 
local effect of topical tacrolimus is probably due to its immunosuppressive effects 
(blocking calcineurin signal pathway, inhibiting tumor necrosis factor-alpha secretion in 
human keratinocytes and inhibiting collagen synthesis) [7]. 
With the patient presented here we want to report another case of rapid improvement 
of an atypical plaque-like sclerodermiform mucinosis that caused considerable 
impairment of the patient’s quality of life due to skin hardening of the nuchal area, and 
we want to expand the possible applications of topical tacrolimus in dermatology. 
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Fig. 1. Extensive sclerodermiform plaque of the neck and shoulder area. 
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Fig. 2. Left: Hematoxylin and eosin-stained slide, ×200. Superficial dermal perivascular inflammatory 
lymphocytic infiltrate. Striking perifollicular and interstitial deposition of mucin without substantial 
increase of interstitial fibroblasts. Right: Colloidal iron-stained slide, ×200. Deposition of interstitial 
mucin. 
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